Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1

Journal of Virology

Volumn 75, Issue 24, 2001, Pages 12161-12168

  Hezareh, M ^a   Hessell, A J ^a   Jensen, R C ^a   Van De Winkel, J G J ^a   Parren, P W H I ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; FC RECEPTOR; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN L234A; PROTEIN L235A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOLYSIS; EFFECTOR CELL; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN CONSTANT REGION; MOLECULAR INTERACTION; NONHUMAN; PHAGOCYTOSIS; POINT MUTATION; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTATION; VIRUS NEUTRALIZATION;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS; RECEPTORS, IGG;

EID: 0035194285     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.24.12161-12168.2001     Document Type: Article

References (60)

1. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope and chimpanzee monoclonal antibodies of different epitope specificities
2. Passive immunization with human immunodeficiency virus type 1-neutralizing monoclonal antibody in hu-PBL-SCID mice: Isolation of a neutralization escape variant
3. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
4. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker
5. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies
6. Complement activation by immunoglobulin does not depend solely on C1q binding
7. Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia
8. Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis
9. Generation of human monoclonal antibodies against HIV-1 proteins; Electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization
10. Immunoglobulin G: Functional sites
11. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals
12. The C1q receptor site on immunoglobulin G
13. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
14. Human antibody effector function
15. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region
16. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodefiency virus type 1
17. Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries
18. The binding site for C1q on IgG
19. Localisation of the binding site for the human high-affinity Fc receptor on IgG
20. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
21. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
22. Pre-and post-exposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody
23. Abnormally short serum half-lives of IgG in β2-microglobulin-deficient mice
24. Human IgG Fc receptors
25. Reaction between the isolated globular sub-units of the complement component C1q and IgG-complexes
26. Binding characteristics of dimeric IgG subclass complexes to human neutrophils
27. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
28. Molecular definition of interaction sites on human IgG for Fc receptors (huFcγR)
29. The protection receptor for IgG catabolism is the beta 2-microglobulin-containing neonatal intestinal transport receptor
30. Recombinant human monoclonal antibody IgG1 b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates
31. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms
32. Efficient site-directed mutagenesis using uracil-containing DNA
33. Multiple binding sites on the CH2 domain of IgG for mouse FcγRII
34. Human FcγRI and FcγRII interact with distinct but overlapping sites on human IgG
35. Protection of macaques against pathogenic SHIV-89.6PD by passive transfer of neutralizing antibodies
36. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
37. Dissociation of gp120 from HIV-1 virions induced by soluble CD4
38. H2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcγRI and FcTRIII binding
39. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
40. The anti-viral activity of antibodies in vitro and in vivo
41. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monodonal antibody against the gp120 CD4-binding site
42. Relevance of the antibody response against human immunodeficiency virus type I envelope to vaccine design
43. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
44. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type-1
45. On the interaction of IgG subclasses with the low affinity FcγRIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2
46. Prevention of HIV infection by passive immunization with HIV immunoglobulin
47. Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fcγ/receptor
48. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex
49. A major histocompatibility complex class I-like Fc receptor cloned from human placenta: Possible role in transfer of immunoglobulin G from mother to fetus
50. Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins
51. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation
52. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
53. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type I
54. FcR gamma-chain is essential for both surface expression and function of human FcγRI (CD64) in vivo
55. A single amino acid change in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding
56. Measurement of direct and indirect forms of anti-HIV ADCC: Implications for other retroviral disease
57. The IgG Fc contains distinct Fc receptor (FcR) binding sites: The leukocyte receptors FcγRI and FcγRIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A
58. Localisation of the monocyte-binding region on human immunoglobulin G
59. In vitro characterization of five humanized OKT3 effector function variant antibodies
60. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41